RxDoctor Payments Data

Jane Cleveland, PA

Medical · Newburyport, MANPI 1407839731

Payments from drug & device makers

$229in general payments, 2019–2025

Across 11 payments — averaging $20.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$60
  • Biohaven Pharmaceuticals, Inc.$53
  • Lilly USA, LLC$31
  • Novo Nordisk$29
  • AstraZeneca$21
  • Johnson & Johnson$21
  • plus $13 from 1 others

What the payments were for

  • Food & beverage$21795%
  • Education$125%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$229 in reported general payments places this provider in the 55th percentile of 421 medical providers in Massachusetts.

See all medical providers in Massachusetts

Medicare billing

Part B allowed, 2024
$83,739
Medicare patients
205
Services billed
1,561

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide70$90,366
EliquisApixaban77$70,214
TrulicityDulaglutide46$55,284
JardianceEmpagliflozin46$37,923
ProliaDenosumab17$28,551
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$21,642
XareltoRivaroxaban13$13,177
NamzaricMemantine Hcl/Donepezil Hcl14$8,483
Tresiba Flextouch U-100Insulin Degludec13$6,304
Rosuvastatin Calcium225$5,674
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$4,902
Olmesartan Medoxomil179$4,575
Incruse ElliptaUmeclidinium Bromide13$3,924
Potassium Chloride42$3,186
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate11$2,216

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$31$145,651116 claims
Boehringer IngelheimJardiance$60$37,92346 claims
Johnson & JohnsonXarelto$21$13,17713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 421 medical providers in Massachusetts.

Other medical in Newburyport

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →